Clinical Trials Browser

Metastatic Castration-resistant Prostate Cancer (mCRPC) × pembrolizumab × 1 year × Clear all

NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Phase 1 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)